Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to organize regulatory and related disclosures associated with the ticker symbol ALPS. Public information shows that the symbol has been used in connection with both ALPS Group Inc, a biotechnology research and healthcare platform, and Alpine Summit Energy Partners, Inc., a U.S.-based company that operated and developed oil and gas assets. While no specific SEC filings are listed in the available data for ALPS Group Inc, historical references to Alpine Summit Energy Partners, Inc. mention filings such as Form 8-K and other reports accessible through EDGAR and SEDAR.
For ALPS Group Inc, investors typically look to SEC filings such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K for information about its integrated biotechnology platform, its role as parent of Alps Life Sciences Inc, and the details of its business combination with Globalink Investment Inc. These filings would be expected to describe the company’s focus on predictive, preventive, and precision medicine, its corporate structure, and risk factors relevant to its biotechnology and healthcare operations.
For Alpine Summit Energy Partners, Inc., historical filings referenced in news releases include a Form 8-K related to shareholder meeting results and other reports that discuss its operations and financial performance as an oil and gas company. The company also announced a voluntary Chapter 11 process in the U.S. Bankruptcy Court for the Southern District of Texas, which is typically accompanied by court and related disclosure documents.
On a platform that aggregates ALPS filings, users can expect near real-time updates sourced from EDGAR when available, along with tools that provide AI-generated summaries of lengthy documents such as 10-K and 10-Q reports. Such summaries can help clarify segment information, key risk disclosures, and major corporate events. Where insider transaction reports on Form 4 exist for companies associated with the ALPS ticker, they can offer additional insight into equity transactions by directors and officers.
Alps Group Inc has appointed Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026, expanding the Board from five to six members. He is considered independent under Nasdaq rules and is expected to join both the Audit Committee and the Compensation Committee.
Mr. Lee is a New York-licensed Certified Public Accountant with more than three decades of public accounting and advisory experience, including as a Partner at Ernst & Young LLP and long-standing advisory work with the International Swaps and Derivatives Association. The company operates an integrated biotechnology and healthcare platform focused on predictive, preventive, and precision medicine.
Alps Group Inc officer Poh Chit Laa has filed an initial statement of beneficial ownership. The filing shows direct ownership of 2,000 Ordinary Shares as of March 18, 2026. This Form 3 does not report any recent purchase, sale, or option exercise, only the existing share position.
Alps Group Inc director Chua Boon Ping filed an initial ownership report showing a direct holding of 150,000 Ordinary Shares. This Form 3 does not record a new purchase or sale but establishes the director’s existing equity stake and confirms direct ownership of these shares.
Alps Group Inc director Chew Yoke Ling has filed an initial ownership report showing a substantial equity stake in the company. The Form 3 discloses direct ownership of 6,882,720 Ordinary Shares as of the reported date. This filing records existing holdings and does not reflect any new buy or sell transaction.
Alps Group Inc executive Cheing Lye-Ping, the Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, indicating no insider trading activity is disclosed in this excerpt.
Alps Group Inc director Mohamed Suleiman bin has filed an initial ownership report on Form 3. This filing establishes his status as a director of the company and indicates that there are currently no reportable transactions or derivative positions listed in the submission.
Alps Group Inc executive Manickam Ravichandran, the Chief Scientific Officer, has filed an initial insider ownership report. The filing shows direct ownership of 20,000 Ordinary Shares, establishing his reported equity stake in the company but not reflecting any recent buy or sell transaction.
Alps Group Inc executive Low Wei Sim, the Chief Operating Officer, has filed an initial ownership report showing a direct holding of 821,083 Ordinary Shares. This filing is a Form 3, which records the officer’s existing stake and does not reflect a new buy or sell transaction.
Alps Group Inc director and Chief Executive Officer Tham Seng Kong filed an initial ownership report showing a substantial direct stake in the company. The filing reports beneficial ownership of 77,144,380 Ordinary Shares, confirming his status as a major, more than ten percent, shareholder.
Alps Group Inc filed a Form 6-K highlighting a peer-reviewed case series of its autologous Natural Killer (NK) cell therapy using an in-house culture protocol. The study in SAGE Open Medical Case Reports followed nine patients treated at ALPS Medical Centre between 2023 and 2024.
Patients were monitored for blood counts, liver function, hypersensitivity, inflammatory markers and tumor markers to evaluate safety and potential toxic or dose-dependent adverse reactions. The case series provided evidence of clinical tolerability of autologous NK cells produced with the company’s proprietary protocol and complied with Malaysian Good Clinical Practice and the Declaration of Helsinki.
The company also emphasized a patent-pending, antibody-free culture method that aims to enable cost-effective, large-scale production of highly pure NK cells using basic media and autologous plasma. These preliminary data, together with preclinical GLP findings, are intended to support future clinical investigations in a broader patient population.